NYSE:PBH

Prestige Consumer Healthcare Competitors

$45.22
+0.19 (+0.42 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$44.88
Now: $45.22
$45.73
50-Day Range
$41.71
MA: $44.31
$47.63
52-Week Range
$32.19
Now: $45.22
$47.98
Volume242,883 shs
Average Volume566,004 shs
Market Capitalization$2.25 billion
P/E Ratio14.04
Dividend YieldN/A
Beta0.76

Competitors

Prestige Consumer Healthcare (NYSE:PBH) Vs. BBIO, MRTX, RARE, ARWR, GWPH, and ASND

Should you be buying PBH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Prestige Consumer Healthcare, including BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), and Ascendis Pharma A/S (ASND).

Prestige Consumer Healthcare (NYSE:PBH) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Prestige Consumer Healthcare and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prestige Consumer Healthcare17.03%13.76%4.80%
BridgeBio PharmaN/A-109.88%-48.54%

Valuation & Earnings

This table compares Prestige Consumer Healthcare and BridgeBio Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$963.01 million2.34$142.28 million$2.9615.28
BridgeBio Pharma$40.56 million202.43$-260,590,000.00($2.48)-22.23

Prestige Consumer Healthcare has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.5% of BridgeBio Pharma shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Prestige Consumer Healthcare and BridgeBio Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prestige Consumer Healthcare03302.50
BridgeBio Pharma01902.90

Prestige Consumer Healthcare presently has a consensus target price of $87.60, suggesting a potential upside of 93.72%. BridgeBio Pharma has a consensus target price of $72.8889, suggesting a potential upside of 32.24%. Given Prestige Consumer Healthcare's higher probable upside, equities analysts clearly believe Prestige Consumer Healthcare is more favorable than BridgeBio Pharma.

Summary

Prestige Consumer Healthcare beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.

Prestige Consumer Healthcare (NYSE:PBH) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Institutional and Insider Ownership

94.9% of Mirati Therapeutics shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Prestige Consumer Healthcare and Mirati Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prestige Consumer Healthcare03302.50
Mirati Therapeutics151002.56

Prestige Consumer Healthcare presently has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Mirati Therapeutics has a consensus target price of $218.5714, suggesting a potential upside of 38.17%. Given Prestige Consumer Healthcare's higher probable upside, equities analysts clearly believe Prestige Consumer Healthcare is more favorable than Mirati Therapeutics.

Valuation & Earnings

This table compares Prestige Consumer Healthcare and Mirati Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$963.01 million2.34$142.28 million$2.9615.28
Mirati Therapeutics$3.34 million2,398.14$-213,260,000.00($5.69)-27.80

Prestige Consumer Healthcare has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Profitability

This table compares Prestige Consumer Healthcare and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prestige Consumer Healthcare17.03%13.76%4.80%
Mirati TherapeuticsN/A-60.01%-54.21%

Summary

Prestige Consumer Healthcare beats Mirati Therapeutics on 8 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ultragenyx Pharmaceutical and Prestige Consumer Healthcare, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
Prestige Consumer Healthcare03302.50

Ultragenyx Pharmaceutical presently has a consensus target price of $131.20, suggesting a potential upside of 20.68%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Ultragenyx Pharmaceutical.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77
Prestige Consumer Healthcare$963.01 million2.34$142.28 million$2.9615.28

Prestige Consumer Healthcare has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
Prestige Consumer Healthcare17.03%13.76%4.80%

Summary

Prestige Consumer Healthcare beats Ultragenyx Pharmaceutical on 8 of the 12 factors compared between the two stocks.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Arrowhead Pharmaceuticals and Prestige Consumer Healthcare, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arrowhead Pharmaceuticals021002.83
Prestige Consumer Healthcare03302.50

Arrowhead Pharmaceuticals presently has a consensus target price of $85.3077, suggesting a potential upside of 26.10%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Arrowhead Pharmaceuticals.

Valuation and Earnings

This table compares Arrowhead Pharmaceuticals and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$87.99 million79.80$-84,550,000.00($0.84)-80.54
Prestige Consumer Healthcare$963.01 million2.34$142.28 million$2.9615.28

Prestige Consumer Healthcare has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares Arrowhead Pharmaceuticals and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%
Prestige Consumer Healthcare17.03%13.76%4.80%

Summary

Prestige Consumer Healthcare beats Arrowhead Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for GW Pharmaceuticals and Prestige Consumer Healthcare, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GW Pharmaceuticals010402.29
Prestige Consumer Healthcare03302.50

GW Pharmaceuticals presently has a consensus target price of $204.0909, suggesting a potential downside of 6.77%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than GW Pharmaceuticals.

Valuation and Earnings

This table compares GW Pharmaceuticals and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GW Pharmaceuticals$311.33 million22.04$-9,020,000.00($0.24)-912.08
Prestige Consumer Healthcare$963.01 million2.34$142.28 million$2.9615.28

Prestige Consumer Healthcare has higher revenue and earnings than GW Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

GW Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares GW Pharmaceuticals and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GW Pharmaceuticals-11.05%-7.46%-6.13%
Prestige Consumer Healthcare17.03%13.76%4.80%

Summary

Prestige Consumer Healthcare beats GW Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Profitability

This table compares Ascendis Pharma A/S and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%
Prestige Consumer Healthcare17.03%13.76%4.80%

Volatility and Risk

Ascendis Pharma A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Valuation and Earnings

This table compares Ascendis Pharma A/S and Prestige Consumer Healthcare's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$14.98 million437.57$-244,180,000.00($5.25)-23.23
Prestige Consumer Healthcare$963.01 million2.34$142.28 million$2.9615.28

Prestige Consumer Healthcare has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ascendis Pharma A/S and Prestige Consumer Healthcare, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ascendis Pharma A/S011102.92
Prestige Consumer Healthcare03302.50

Ascendis Pharma A/S presently has a consensus target price of $187.6667, suggesting a potential upside of 53.89%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 93.72%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Ascendis Pharma A/S.

Summary

Prestige Consumer Healthcare beats Ascendis Pharma A/S on 8 of the 12 factors compared between the two stocks.


Prestige Consumer Healthcare Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.12+0.3%$8.21 billion$40.56 million-16.16
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$158.19+3.7%$8.01 billion$3.34 million-20.54Unusual Options Activity
News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72+0.8%$7.28 billion$103.71 million-24.77Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65+0.5%$7.02 billion$87.99 million-80.54News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90+0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95+1.8%$6.55 billion$14.98 million-14.85Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78+2.3%$6.30 billion$150,000.00-21.12Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78+0.6%$5.74 billion$1.12 billion84.96
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80+1.2%$5.70 billion$380.83 million-9.18Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62+1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50+3.5%$5.55 billionN/A-38.14Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20+0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$77.90+0.6%$5.45 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15+0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40+1.9%$4.62 billionN/A-6.06Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.64+1.2%$4.36 billion$6.87 million-7.21Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25+0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64+4.1%$4.16 billion$1.11 billion24.96Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69+0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94+2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57+1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03+5.8%$3.58 billionN/A-20.81Analyst Report
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00+1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00+0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59+0.8%$3.42 billion$306.98 million-6.95
Insmed logo
INSM
Insmed
1.2$33.07+1.7%$3.42 billion$136.47 million-12.72News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15+0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87+1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54+1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87+0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69+2.6%$3.16 billion$42.98 million-25.27Analyst Upgrade
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60+4.2%$3.04 billionN/A-56.02Insider Selling
MorphoSys logo
MOR
MorphoSys
0.3$22.65+2.3%$2.98 billion$80.43 million107.86Decrease in Short Interest
OPKO Health logo
OPK
OPKO Health
1.9$4.34+0.5%$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64+1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07+5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46+5.3%$2.75 billion$260.98 million-357.67Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00+0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39+0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77+0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94+3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81+1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22+3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23+0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26+5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73+0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57+2.6%$2.35 billion$33.94 million-88.91
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13+5.6%$2.35 billion$15 million-17.35Unusual Options Activity
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.